Oscar Health Q1 revenue miss draws investor focus

Oscar Health (OSCR) is back in focus after reporting year on year revenue growth that still came in below analyst forecasts, a contrast with other health insurance providers that broadly surpassed Q1 revenue estimates.

Oscar Health's share price has pulled back 3.16% over the last day and 4.71% over the past week, yet still shows strong upward momentum with a 30 day share price return of 28.30% and a 3 year total shareholder return of 252.10%. This suggests the revenue miss is being weighed against a much stronger multi year rerating of the stock.

If Oscar Health's recent moves have your attention, this could be a good moment to broaden your view and look at other healthcare focused AI opportunities through the 40 healthcare AI stocks

With Oscar Health now trading above the average analyst price target and carrying a modest value score of 3, investors may need to consider whether the recent gains leave limited upside or whether the stock still reflects future growth potential.

Most Popular Narrative: 26.2% Overvalued

Oscar Health's most followed valuation narrative points to a fair value of $22.60, which sits well below the last close at $28.52, setting up a clear tension between model and market.

The analysts have a consensus price target of $22.6 for Oscar Health based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $35.0, and the most bearish reporting a price target of just $13.0.

Curious what kind of revenue trajectory, margin uplift and future earnings multiple are baked into that $22.60 figure, and how those assumptions handle Oscar Health's ACA exposure and policy risk over time.

Result: Fair Value of $22.60 (OVERVALUED)

However, for Oscar Health to close the gap with that $22.60 fair value narrative, investors still need to see ACA repricing hold up and policy risks around subsidies remain manageable.

Another View On Oscar Health's Valuation

The analyst narrative frames Oscar Health as 26.2% overvalued relative to a $22.60 fair value. However, the market is currently paying only 0.6x P/S compared with 1.2x for both peers and the wider US insurance industry, and a fair ratio of 0.7x in the SWS model. That gap points to either a margin of safety or a signal that investors are still cautious on future execution. Which side do you think is closer to the truth?

Next Steps

If the mixed signals around Oscar Health leave you unsure, act while the data is fresh and carefully weigh the trade off between risks and rewards using the 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond Oscar Health?

If Oscar Health has sharpened your focus, do not stop here. Use the Simply Wall Street Screener to uncover other stocks that might better fit your approach.

• Target potential mispricing by scanning companies with strong fundamentals and appealing valuations through the 43 high quality undervalued stocks.
• Prioritize resilience by reviewing companies that appear on the 74 resilient stocks with low risk scores to see which stocks carry lower risk scores.
• Spot lesser known opportunities by searching the screener containing 19 high quality undiscovered gems that combine quality metrics with relatively limited market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.